Results 201 to 210 of about 7,990,092 (312)

Federal and Industry Sponsorship in US Cancer Clinical Trials.

JAMA Oncol
Unger JM, Xiao H, LeBlanc ML, Hershman DL.   +3 more
europepmc   +1 more source

Blinded-Into-Unblinded Interim Analyses for Clinical Trials With Time-to-Event Endpoints. [PDF]

Biom J
Schüürhuis S, Meis J, Bokelmann B, Kieser M, Herrmann C.   +4 more
europepmc   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Cross-sectional analysis of safety reporting in sleep disorder clinical trials. [PDF]

BMJ Open
Lackey M, Forbes C, Keefer K, Hazlitt R, Harris T, Archer D, Corwin L, Ford AI, Vassar M.   +8 more
europepmc   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

A Registry-Based Perspective of Interventional Clinical Trials for Duchenne Muscular Dystrophy. [PDF]

Cureus
Chaudhary JH, Chacko JO, Susarla V, Kashyap Peraboina SS, Sen S.   +4 more
europepmc   +1 more source

Clinical trial methodology

Nature, 1978
openaire   +3 more sources

Report From the Panel on the Case for Registers of Clinical Trials at the Eigth Annual Meeting of the Society for Clinical Trials

, 1988
Dickersin, Kay
core  

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials. [PDF]

Front Neurol
Mahmoudi F, Baldwin N, Flores Gonzalez R, Nittala S, Rammohan K, McCarthy M, Nelson F.   +6 more
europepmc   +1 more source